Navigation Links
Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
Date:6/30/2011

e death rates are generally low, the highly infectious nature of the virus has a profound negative economic impact, such as in the dairy industry where cattle may experience reduced milk production, poor growth and permanent hoof damage. An FMD outbreak typically leads to economic sanctions, including the loss of export markets, and can negatively impact tourism as restrictions are placed on the movement of people and animals. This was the case in the 2001 outbreak in the UK.

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio clinical programs include three Phase II studies for vaccines treating cervical dysplasia/cancer, hepatitis C virus, and leukemia. Other clinical programs target influenza (preventive) and HIV (preventive and therapeutic). Inovio partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development progr
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
2. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
5. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
6. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
7. Amylin Pharmaceuticals to Present Promising New Data on the Companys Diabetes Programs at ADA 2011
8. MKM Partners Hires Biotechnology/Specialty Pharmaceuticals Analyst
9. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
10. FDA Grants Fast Track Designation to Tioga Pharmaceuticals Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
11. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Celsion Corporation (the "Company") (NASDAQ: ... from two institutional healthcare investors to purchase an aggregate ... in an at-the-market registered direct offering and a concurrent ... The Company entered into a definitive purchase agreement ... to sell an aggregate of 3,000,000 shares of its ...
(Date:5/28/2015)... McKinney, Texas (PRWEB) May 28, 2015 ... products for use in applications such as animal ... fat and oil reduction in wastewater treatment plants ... be attending the World Pork Expo, June 3-5 ... earlier this year in a Wall Street Journal ...
(Date:5/28/2015)... NORTH BRUNSWICK, N.J. , May 28, 2015 ... that PDS0101, a cancer immunotherapy treatment targeting HPV-16, ... patients.  Currently, pre-cervical cancer is ... could offer a simple and effective non-surgical alternative. ... body,s defense mechanisms (T-cells) to recognize, target, and ...
(Date:5/28/2015)... BEACH, Fla. , May 28, 2015 ... supporting the anti-cancer potential of its growth hormone-releasing hormone ... at the 2015 ASCO Annual Meeting. The data ... target for Biscayne,s anti-cancer GHRH blockers, is present on ... status. These findings suggest that GHRH antagonists could have ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3DryLet to Showcase Patented ManureMagic™ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... April 15, 2011 Carmell Therapeutics, a company that ... of injured tissues, has closed on a Series A ... facility and collect data for early clinical validation for ... was led by Harbor Light Capital Partners, a private ...
... Therapeutics, Inc. (Nasdaq: HALO ) today announced ... patients who receive their insulin treatment with a ... Halozyme,s rHuPH20 (recombinant human hyaluronidase) with the active ingredient ... of action. These preliminary results represent the first reported ...
... Promising new devices for mechanical circulatory support of ... research, will be revealed this week at the International ... Meeting and Scientific Sessions. An update from the Pumps ... presented during the Meeting in San Diego.  PumpKIN is ...
Cached Biology Technology:Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 2Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 3Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 4Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 2Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 3
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... to tackle wheat,s worst enemy , Unlocking ancient rice ... in aphids, mouths, Reducing crop losses with cereals that ... better Indian varieties , Over 40 international research organisations ... will harness bioscience to improve food security in developing ...
... the physical process that creates that oh-so-alluring new car ... out, not particularly wholesome for sensitive satellite instruments, either. But ... to protect those instruments from its ill effects. ... car is its factory-fresh new car smell, a distinctive aroma ...
... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... that its Board of Directors has declared a special cash ... total.  The special cash dividend will be paid on December ... 2012.  The Board of Directors has determined ...
Cached Biology News:Major international push to maximize bioscience research to help world's poorest farmers 2Major international push to maximize bioscience research to help world's poorest farmers 3Major international push to maximize bioscience research to help world's poorest farmers 4Ah, that new car smell: NASA technology protects spacecraft from outgassed molecular contaminants 2Ah, that new car smell: NASA technology protects spacecraft from outgassed molecular contaminants 3Aware, Inc. Declares Special Cash Dividend of $1.80 Per Share, or Approximately $40 Million in Total 2
... anti-Human Alpha 1 Acid Glycoprotein ... Goats were immunized with ... in Freund's adjuvant. The ... to ensure specificity. For ...
...
... Development kit contains the basic components required ... measure natural and recombinant canine Monocyte Chemotactic ... and serum.1 Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Biology Products: